25th March 2024
Coventry, UK (25 March 2024): Medherant Limited (“Medherant”) announces that it has entered into a Development Collaboration Agreement with Bayer for the development of a transdermal patch product for delivery of an a
18th October 2023
Did you know that peri-menopause and menopause affects over 13 million women in the UK?
13th October 2023
The first group of volunteers has been dosed and further groups will participate in the study over the coming months.
2nd October 2023
The study will be conducted by Hammersmith Medicines Research (HMR; London) and enrol up to 24 women to investigate the safety, tolerability and pharmacokinetics of testosterone delivered from Medherant TEPI Patch whe
11th September 2023
11 September 2023 (Coventry, UK). Medherant announces that Dr Karolina Afors BSC MBBS MRCOG has joined the company in the newly-created role of Medical Director to lead the clinical development of the
BVCA Management Team Awards
14th June 2019
Medherant enjoyed a great evening at the Midlands BVCA Management Team Awards last night.
Silicone republic 100
11th February 2019
Medherant has been included in the Silicone Republic Europe Start-up 100 for 2019 which looks at the companies to watch this year in e-commerce and fintech, deeptech, hardware and IoT, and medtech and life sciences.
CPhI awards logo
11th September 2018
Medherant has been shortlisted for the CPhI Pharma Awards in both the Formulation and Drug Delivery Devices categories for its TEPI Patch® technology.
Mednous
6th June 2018
Transdermal drug delivery systems have been used in different forms since ancient times.
14th February 2018
There are many problems linked to oral drug administration including first pass metabolism, gastrointestinal tract damage and low levels of drug reaching the target site.

Pages